<?xml version="1.0" encoding="UTF-8"?>
<PAPER>

<BODY>
<DIV><P>
</P>
<P>[0001] PROCESS FOR THE PREPARATION OF <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.99" epochem-id="EPOCHEM:NEW:COMPOUND:1686" name="DULOXETINE" comment="" chebi-id="CHEBI:36796" relevant="true">DULOXETINE</ne>
Field of the invention
The present invention relates to a process for the preparation of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.29" epochem-id="EPOCHEM:COMPOUND:3701" name="1-naphthol" comment="" chebi-id="CHEBI:10319" relevant="false">1-naphthol</ne> mixed ethers, in particular of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.100" epochem-id="EPOCHEM:NEW:COMPOUND:1686" name="DULOXETINE" comment="" chebi-id="CHEBI:36796" relevant="true">duloxetine</ne> Ia:
</P>
<P>[0004]
EMI2.1
</P>
<P>1a
Background of the invention
The preparation of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.30" epochem-id="EPOCHEM:COMPOUND:3701" name="1-naphthol" comment="" chebi-id="CHEBI:10319" relevant="false">1-naphthol</ne> mixed ethers raises remarkable interest, since it regards, for example, the synthesis of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.101" epochem-id="EPOCHEM:NEW:COMPOUND:1686" name="DULOXETINE" comment="" chebi-id="CHEBI:36796" relevant="true">duloxetine</ne> Ia (<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.120" epochem-id="EPOCHEM:NEW:COMPOUND:1688" name="(+)-(S)-N-methyl -[gamma]-(l-naphthalenyloxy)-2-thiophenepropanamine" comment="" chebi-id="WO2007045405:424056" relevant="true">(+)-(S)-N- methyl-[gamma]-(l-naphthalenyloxy)-2-thiophenepropanamine</ne>), whose <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.64" epochem-id="EPOCHEM:NEW:COMPOUND:455" name="hydrochloride" comment="" chebi-id="CHEBI:36807" relevant="false">hydrochloride</ne> salt is used as <ne type="ONT" id="WO2007045405.HC.class-names.2" epochem-id="EPOCHEM:NEW:CLASS:570" name="antidepressant" comment="" chebi-id="CHEBI:35469" relevant="false">antidepressant</ne>. EP 273 658 discloses two methods for the preparation of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.102" epochem-id="EPOCHEM:NEW:COMPOUND:1686" name="DULOXETINE" comment="" chebi-id="CHEBI:36796" relevant="true">duloxetine</ne> or of its precursor Ib:
</P>
<P>[0008]
EMI2.2
</P>
<P>1b
A first procedure comprises the use of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.31" epochem-id="EPOCHEM:COMPOUND:3701" name="1-naphthol" comment="" chebi-id="CHEBI:10319" relevant="false">1-naphthol</ne> 3a
</P>
<P>[0011]
EMI2.3
</P>
<P>3a and of compounds of formula 2.
</P>
<P>[0013]
EMI3.1
</P>
<P>2
in particular compound 2a in which X = <ne type="LIGAND" id="WO2007045405.HC.ligand-names.2" epochem-id="EPOCHEM:NEW:LIGAND:626" name="N(CH3)2" comment="" chebi-id="WO2007045405:489830" relevant="false">N(CH3)2</ne>. The <ne id="WO2007045405.HC.class-names.17" epochem-id="EPOCHEM:NEW:CLASS:1160" name="ether" comment="" chebi-id="CHEBI:25698" relevant="false" type="CLASS">ether</ne> bond in compounds Ia and Ib forms through Mitsunobu reaction, which consists in the treatment in a <ne id="WO2007045405.HC.class-names.18" epochem-id="EPOCHEM:NEW:CLASS:1160" name="ether" comment="" chebi-id="CHEBI:25698" relevant="false" type="CLASS">ether</ne> <ne type="ONT" id="WO2007045405.HC.class-names.6" epochem-id="EPOCHEM:NEW:CLASS:770" name="solvent" comment="" chebi-id="CHEBI:46787" relevant="false">solvent</ne>, for example <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.124" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne>, of compounds 3a and 2 with equimolecular amounts of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.32" epochem-id="EPOCHEM:NEW:COMPOUND:738" name="triphenylphosphine" comment="" chebi-id="WO2007045405:882968" relevant="false">triphenylphosphine</ne> and of an <ne id="WO2007045405.HC.class-names.1" epochem-id="EPOCHEM:NEW:CLASS:159" name="azodicarboxylic acid ester" comment="" chebi-id="WO2007045405:157236" relevant="false" type="CLASS">azodicarboxylic acid ester</ne> (typically the <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.35" epochem-id="EPOCHEM:NEW:COMPOUND:739" name="diisopropyl ester" comment="" chebi-id="WO2007045405:196171" relevant="false">diisopropyl ester</ne>). In this way the <ne id="WO2007045405.HC.class-names.19" epochem-id="EPOCHEM:NEW:CLASS:1160" name="ether" comment="" chebi-id="CHEBI:25698" relevant="false" type="CLASS">ether</ne> bond forms with inversion of configuration, obtaining as by-products equimolecular amounts of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.33" epochem-id="EPOCHEM:NEW:COMPOUND:738" name="triphenylphosphine" comment="" chebi-id="WO2007045405:882968" relevant="false">triphenylphosphine</ne> oxide and <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.125" epochem-id="EPOCHEM:NEW:COMPOUND:1964" name="diisopropyl hydrazodicarboxylate" comment="" chebi-id="WO2007045405:804901" relevant="false">diisopropyl hydrazodicarboxylate</ne>, whose separation from the desired <ne id="WO2007045405.HC.class-names.20" epochem-id="EPOCHEM:NEW:CLASS:1160" name="ether" comment="" chebi-id="CHEBI:25698" relevant="false" type="CLASS">ether</ne> is troublesome. The X substituent in compounds 2 can be, further to <ne type="LIGAND" id="WO2007045405.HC.ligand-names.1" epochem-id="EPOCHEM:NEW:LIGAND:465" name="-N(CH3)2" comment="" chebi-id="WO2007045405:382681" relevant="false">-N(CH3)2</ne>, any good leaving group susceptible of being substituted with a <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.70" epochem-id="EPOCHEM:NEW:COMPOUND:749" name="nitrogen" comment="" chebi-id="CHEBI:25555" relevant="false">nitrogen</ne> function which allows to obtain <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.36" epochem-id="EPOCHEM:NEW:COMPOUND:740" name="(+)- duloxetine" comment="" chebi-id="WO2007045405:637660" relevant="true">(+)- duloxetine</ne> Ia. The Mitsunobu reaction with compound 2a proceeds in more than 24 h. The equimolar ratio of the two reagents (<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.34" epochem-id="EPOCHEM:NEW:COMPOUND:738" name="triphenylphosphine" comment="" chebi-id="WO2007045405:882968" relevant="false">triphenylphosphine</ne> and <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.37" epochem-id="EPOCHEM:NEW:COMPOUND:741" name="azodicarboxylate" comment="" chebi-id="WO2007045405:404694" relevant="false">azodicarboxylate</ne>) with respect to compounds 2 and 3a and the prolonged reaction times make this synthetic procedure not very profitable, even if it proceeds with inversion of configuration at the oxygen-bearing carbon in compounds 2.
A method for the synthesis of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.104" epochem-id="EPOCHEM:NEW:COMPOUND:1686" name="DULOXETINE" comment="" chebi-id="CHEBI:36796" relevant="true">duloxetine</ne> Ia that is preferred to the one reported above envisages the use of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.4" epochem-id="EPOCHEM:NEW:COMPOUND:735" name="1-fluoronaphthalene" comment="" chebi-id="WO2007045405:69693" relevant="true">1-fluoronaphthalene</ne> 3b
</P>
<P>[0017]
EMI3.2
</P>
<P>3b and 2a as substrates. Compound 2a is converted to the corresponding <ne id="WO2007045405.HC.class-names.3" epochem-id="EPOCHEM:NEW:CLASS:571" name="alkoxide" comment="" chebi-id="WO2007045405:874546" relevant="false" type="CLASS">alkoxide</ne> by treatment with a strong base, for example <ne type="FORMULA" id="WO2007045405.HC.formula-names.1" epochem-id="EPOCHEM:NEW:FORMULA:46" name="NaH" comment="" chebi-id="WO2007045405:943979" relevant="false">NaH</ne>; the <ne id="WO2007045405.HC.class-names.4" epochem-id="EPOCHEM:NEW:CLASS:571" name="alkoxide" comment="" chebi-id="WO2007045405:874546" relevant="false" type="CLASS">alkoxide</ne> replaces the <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.118" epochem-id="EPOCHEM:NEW:COMPOUND:512" name="fluorine" comment="" chebi-id="CHEBI:24061" relevant="false">fluorine</ne> at position 1 of 3b, leading to Ib. The substitution reaction of the <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.119" epochem-id="EPOCHEM:NEW:COMPOUND:512" name="fluorine" comment="" chebi-id="CHEBI:24061" relevant="false">fluorine</ne> on the aromatic ring is a particular reaction which involves an ionic intermediate {Meisenheimer intermediate) and which occurs, according to the state of the art, in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.38" epochem-id="EPOCHEM:NEW:COMPOUND:742" name="N,N-dimethylacetamide" comment="" chebi-id="WO2007045405:14476" relevant="false">N,N-dimethylacetamide</ne> and <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.40" epochem-id="EPOCHEM:NEW:COMPOUND:743" name="dimethylsulfoxide" comment="" chebi-id="WO2007045405:468999" relevant="false">dimethylsulfoxide</ne>. When <ne type="FORMULA" id="WO2007045405.HC.formula-names.2" epochem-id="EPOCHEM:NEW:FORMULA:46" name="NaH" comment="" chebi-id="WO2007045405:943979" relevant="false">NaH</ne> is used as the base in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.121" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>, a temperature of 60-70&lt;0&gt;C must not be exceeded. In particular, according to EP 273 658, compound Ib is obtained from 3b and 2a in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.39" epochem-id="EPOCHEM:NEW:COMPOUND:742" name="N,N-dimethylacetamide" comment="" chebi-id="WO2007045405:14476" relevant="false">N,N-dimethylacetamide</ne>, by treatment of 2 with <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.68" epochem-id="EPOCHEM:NEW:COMPOUND:748" name="Sodium hydride" comment="" chebi-id="WO2007045405:35319" relevant="false">sodium hydride</ne>, at a temperature of 70&lt;0&gt;C, to produce the <ne id="WO2007045405.HC.class-names.5" epochem-id="EPOCHEM:NEW:CLASS:571" name="alkoxide" comment="" chebi-id="WO2007045405:874546" relevant="false" type="CLASS">alkoxide</ne>, followed by addition of
<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.5" epochem-id="EPOCHEM:NEW:COMPOUND:735" name="1-fluoronaphthalene" comment="" chebi-id="WO2007045405:69693" relevant="true">1-fluoronaphthalene</ne> 3b in equimolecular amount, heating at 110&lt;0&gt;C for 60 min. The desired product Ib is recovered as crystalline <ne id="WO2007045405.HC.class-names.25" epochem-id="EPOCHEM:NEW:CLASS:1161" name="oxalate" comment="" chebi-id="CHEBI:30623" relevant="false" type="CLASS">oxalate</ne> in 76% yield. Disclosure of the invention It has now been found that the synthesis of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.105" epochem-id="EPOCHEM:NEW:COMPOUND:1686" name="DULOXETINE" comment="" chebi-id="CHEBI:36796" relevant="true">duloxetine</ne>, in particular of its precursor Ib, can be carried out more conveniently from compounds 2 and 3b, if <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.27" epochem-id="EPOCHEM:NEW:COMPOUND:737" name="l,3-dimethyl-2-oxo-hexahydropyrimidine" comment="1,3-dimethyl-2-oxo-hexahydropyrimidine" chebi-id="WO2007045405:140567" relevant="true">l,3-dimethyl-2-oxo-hexahydropyrimidine</ne> (<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.88" epochem-id="EPOCHEM:NEW:COMPOUND:753" name="DMPU" comment="" chebi-id="WO2007045405:224903" relevant="false">DMPU</ne>) is used as the <ne type="ONT" id="WO2007045405.HC.class-names.7" epochem-id="EPOCHEM:NEW:CLASS:770" name="solvent" comment="" chebi-id="CHEBI:46787" relevant="false">solvent</ne> instead of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.47" epochem-id="EPOCHEM:NEW:COMPOUND:746" name="dimethylacetamide" comment="" chebi-id="WO2007045405:145172" relevant="false">dimethylacetamide</ne>.
Accordingly, the invention relates to a process for the preparation of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.106" epochem-id="EPOCHEM:NEW:COMPOUND:1686" name="DULOXETINE" comment="" chebi-id="CHEBI:36796" relevant="true">duloxetine</ne> Ia:
</P>
<P>[0021]
EMI4.1
</P>
<P>1a which comprises the reaction between <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.6" epochem-id="EPOCHEM:NEW:COMPOUND:735" name="1-fluoronaphthalene" comment="" chebi-id="WO2007045405:69693" relevant="true">1-fluoronaphthalene</ne> 3b
EMI5.1
</P>
<P>3b and <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.1" epochem-id="EPOCHEM:NEW:COMPOUND:734" name="3-N,N-dimethylamino-l-(2-thienyl)-propan-l-ol" comment="3-N,N-dimethylamino-1-(2-thienyl)-propan-1-ol" chebi-id="WO2007045405:87489" relevant="true">3-N,N-dimethylamino-l-(2-thienyl)-propan-l-ol</ne> 2a
</P>
<P>[0024]
EMI5.2
to give (CK)-<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.41" epochem-id="EPOCHEM:NEW:COMPOUND:744" name="(S)-N,N- dimethyl-[gamma]-(l-naphthalenyloxy)-2-thiophenepropanamine" comment="" chebi-id="WO2007045405:675844" relevant="false">(S)- N,N-dimethyl-[gamma]-(l-naphthalenyloxy)-2- thiophenepropanamine</ne>) Ib:
</P>
<P>[0025]
EMI5.3
</P>
<P>1b and the conversion of Ib to <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.107" epochem-id="EPOCHEM:NEW:COMPOUND:1686" name="DULOXETINE" comment="" chebi-id="CHEBI:36796" relevant="true">duloxetine</ne> Ia, characterized in that the reaction between 2a and 3b is carried out in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.44" epochem-id="EPOCHEM:NEW:COMPOUND:745" name="1,3- dimethyl-2-oxo-hexahydropyrimidine" comment="" chebi-id="WO2007045405:310677" relevant="false">1,3- dimethyl-2-oxo-hexahydropyrimidine</ne> (<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.89" epochem-id="EPOCHEM:NEW:COMPOUND:753" name="DMPU" comment="" chebi-id="WO2007045405:224903" relevant="false">DMPU</ne>) as the <ne type="ONT" id="WO2007045405.HC.class-names.8" epochem-id="EPOCHEM:NEW:CLASS:770" name="solvent" comment="" chebi-id="CHEBI:46787" relevant="false">solvent</ne>.
Typically, the reaction takes place at a temperature ranging from 70 to
</P>
<P>120&lt;0&gt;C, for a time ranging from 45 min. to 8 hours.
Comparative experiments for the synthesis of Ib from <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.7" epochem-id="EPOCHEM:NEW:COMPOUND:735" name="1-fluoronaphthalene" comment="" chebi-id="WO2007045405:69693" relevant="true">1-fluoronaphthalene</ne> 3b and <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.2" epochem-id="EPOCHEM:NEW:COMPOUND:734" name="3-N,N-dimethylamino-l-(2-thienyl)-propan-l-ol" comment="3-N,N-dimethylamino-1-(2-thienyl)-propan-1-ol" chebi-id="WO2007045405:87489" relevant="true">3-N,N-dimethylamino-l-(2-thienyl)-propan-l-ol</ne>
</P>
<P>2a, carried out using <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.90" epochem-id="EPOCHEM:NEW:COMPOUND:753" name="DMPU" comment="" chebi-id="WO2007045405:224903" relevant="false">DMPU</ne> and <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.48" epochem-id="EPOCHEM:NEW:COMPOUND:746" name="dimethylacetamide" comment="" chebi-id="WO2007045405:145172" relevant="false">dimethylacetamide</ne> as solvents, proved that
<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.91" epochem-id="EPOCHEM:NEW:COMPOUND:753" name="DMPU" comment="" chebi-id="WO2007045405:224903" relevant="false">DMPU</ne> is economically more advantageous than <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.49" epochem-id="EPOCHEM:NEW:COMPOUND:746" name="dimethylacetamide" comment="" chebi-id="WO2007045405:145172" relevant="false">dimethylacetamide</ne>, as it requires lower reaction temperatures, shorter reaction times and provides higher yields. Typically, compound Ib is recovered as the <ne id="WO2007045405.HC.class-names.26" epochem-id="EPOCHEM:NEW:CLASS:1161" name="oxalate" comment="" chebi-id="CHEBI:30623" relevant="false" type="CLASS">oxalate</ne>, which is subsequently hydrolysed and subjected to fractional crystallization with <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.57" epochem-id="EPOCHEM:COMPOUND:157" name="tartaric acid" comment="" chebi-id="CHEBI:15674" relevant="false">tartaric acid</ne>; compound Ib is recovered again by hydrolysis and each enantiomer is demethylated to give <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.108" epochem-id="EPOCHEM:NEW:COMPOUND:1686" name="DULOXETINE" comment="" chebi-id="CHEBI:36796" relevant="true">duloxetine</ne> Ia. <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.109" epochem-id="EPOCHEM:NEW:COMPOUND:1686" name="DULOXETINE" comment="" chebi-id="CHEBI:36796" relevant="true">Duloxetine</ne> enantiomers are also separated by fractional crystallization of the respective <ne id="WO2007045405.HC.class-names.13" epochem-id="EPOCHEM:NEW:CLASS:429" name="oxalates" comment="" chebi-id="WO2007045405:918973" relevant="false" type="CLASS">oxalates</ne>, hydrolysis of the salts, conversion to <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.65" epochem-id="EPOCHEM:NEW:COMPOUND:455" name="hydrochloride" comment="" chebi-id="CHEBI:36807" relevant="false">hydrochloride</ne> and recrystallization from <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.59" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne>.
The invention is illustrated in greater detail in the following experimental section.
Experimental section
</P>
<P>1. Comparative experiments - Synthesis of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.67" epochem-id="EPOCHEM:NEW:COMPOUND:747" name="(+)-(S)-N,N-dimethyl- [gamma]-(l-naphthalenyloxy)-2-thiophenepropanamine" comment="(+)-(S)-N,N-dimethyl- [gamma]-(1-naphthalenyloxy)-2-thiophenepropanamine" chebi-id="WO2007045405:856111" relevant="false">(+)-(S)-N,N-dimethyl- [gamma]-(l-naphthalenyloxy)-2-thiophenepropanamine</ne>) Ib either in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.50" epochem-id="EPOCHEM:NEW:COMPOUND:746" name="dimethylacetamide" comment="" chebi-id="WO2007045405:145172" relevant="false">dimethylacetamide</ne> or <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.92" epochem-id="EPOCHEM:NEW:COMPOUND:753" name="DMPU" comment="" chebi-id="WO2007045405:224903" relevant="false">DMPU</ne>
<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.69" epochem-id="EPOCHEM:NEW:COMPOUND:748" name="Sodium hydride" comment="" chebi-id="WO2007045405:35319" relevant="false">Sodium hydride</ne> was suspended in either <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.51" epochem-id="EPOCHEM:NEW:COMPOUND:746" name="dimethylacetamide" comment="" chebi-id="WO2007045405:145172" relevant="false">dimethylacetamide</ne> or <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.93" epochem-id="EPOCHEM:NEW:COMPOUND:753" name="DMPU" comment="" chebi-id="WO2007045405:224903" relevant="false">DMPU</ne> in a slight molar excess with respect to alcohol 2a, which was added under stirring and <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.71" epochem-id="EPOCHEM:NEW:COMPOUND:749" name="nitrogen" comment="" chebi-id="CHEBI:25555" relevant="false">nitrogen</ne> atmosphere. The mixture was heated to 70&lt;0&gt;C for 30 min., thereafter <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.8" epochem-id="EPOCHEM:NEW:COMPOUND:735" name="1-fluoronaphthalene" comment="" chebi-id="WO2007045405:69693" relevant="true">1-fluoronaphthalene</ne> 3b was slowly added, keeping again under stirring and <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.72" epochem-id="EPOCHEM:NEW:COMPOUND:749" name="nitrogen" comment="" chebi-id="CHEBI:25555" relevant="false">nitrogen</ne> atmosphere, then the temperature was raised and maintained at 80 or 100&lt;0&gt;C for the required time. After that, the mixture was cooled to room temperature, added with a few ml of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.60" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne> to destroy any excess of <ne type="FORMULA" id="WO2007045405.HC.formula-names.3" epochem-id="EPOCHEM:NEW:FORMULA:46" name="NaH" comment="" chebi-id="WO2007045405:943979" relevant="false">NaH</ne> and poured in 2 volumes of ice, followed by three extractions with 2 volumes of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.127" epochem-id="EPOCHEM:NEW:COMPOUND:2133" name="ethyl ether" comment="" chebi-id="CHEBI:35702" relevant="false">ethyl ether</ne>. The <ne id="WO2007045405.HC.class-names.22" epochem-id="EPOCHEM:NEW:CLASS:1160" name="ether" comment="" chebi-id="CHEBI:35702" relevant="false" type="CLASS">ether</ne> phase was washed three times with 1 volume of water and once with a saturated <ne type="FORMULA" id="WO2007045405.HC.formula-names.5" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne> solution. After drying over <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.79" epochem-id="EPOCHEM:COMPOUND:6847" name="sodium sulfate" comment="" chebi-id="CHEBI:32149" relevant="false">sodium sulfate</ne>, the <ne type="ONT" id="WO2007045405.HC.class-names.9" epochem-id="EPOCHEM:NEW:CLASS:770" name="solvent" comment="" chebi-id="CHEBI:46787" relevant="false">solvent</ne> was evaporated off and the oily residue was taken up in three volumes of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.73" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> and added in the cold with 1.3 molar equiv. of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.126" epochem-id="EPOCHEM:COMPOUND:441" name="oxalic acid" comment="" chebi-id="CHEBI:16995" relevant="false">oxalic acid</ne> in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.74" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne>. The resulting mixture was evaporated to dryness and the solid residue was crystallized from either hot <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.75" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> or <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.128" epochem-id="EPOCHEM:COMPOUND:4306" name="ethyl acetate" comment="" chebi-id="CHEBI:27750" relevant="false">ethyl acetate</ne>/<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.76" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne>. The crystalline <ne id="WO2007045405.HC.class-names.27" epochem-id="EPOCHEM:NEW:CLASS:1161" name="oxalate" comment="" chebi-id="CHEBI:30623" relevant="false" type="CLASS">oxalate</ne> recovered by filtration was dried and weighed.
Ib <ne id="WO2007045405.HC.class-names.28" epochem-id="EPOCHEM:NEW:CLASS:1161" name="oxalate" comment="" chebi-id="CHEBI:30623" relevant="false" type="CLASS">Oxalate</ne>: &lt;1&gt;H NMR (<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.122" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne> - d6) [delta] (8.27 (IH, m), 7.85 (IH, m), 7.53 (2H, m), 7.44 (2H, m), 7.33 (IH, t, J = 7.9 Hz), 7.25 (IH, d, J = 3.4 Hz), 7.04 (IH, d, J = 7.7 Hz), 6.99 (IH, dd, J = 3.5, 5.0 Hz), 6.02 (IH, dd, J = 4.9, 7.7 Hz), 3.25 (IH, m), 3.15 (IH, m), 2.70 (6H, s), 2.58 (IH, m), 2.39 (IH, m).
The experiments were followed over time through GC/MS analysis of sample aliquots and the yield was determined on the weight of Ib <ne id="WO2007045405.HC.class-names.29" epochem-id="EPOCHEM:NEW:CLASS:1161" name="oxalate" comment="" chebi-id="CHEBI:30623" relevant="false" type="CLASS">oxalate</ne> recovered in crystalline pure form after completion of the reaction.
In particular, we calculated the yields in Ib resulting from the addition of 1.05 mol equiv. of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.9" epochem-id="EPOCHEM:NEW:COMPOUND:735" name="1-fluoronaphthalene" comment="" chebi-id="WO2007045405:69693" relevant="true">1-fluoronaphthalene</ne> 3b to 2a sodium salt, that had been obtained with 1.1 mols equiv. of <ne type="FORMULA" id="WO2007045405.HC.formula-names.4" epochem-id="EPOCHEM:NEW:FORMULA:46" name="NaH" comment="" chebi-id="WO2007045405:943979" relevant="false">NaH</ne> (60% suspension in oil) in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.94" epochem-id="EPOCHEM:NEW:COMPOUND:753" name="DMPU" comment="" chebi-id="WO2007045405:224903" relevant="false">DMPU</ne> and <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.52" epochem-id="EPOCHEM:NEW:COMPOUND:746" name="dimethylacetamide" comment="" chebi-id="WO2007045405:145172" relevant="false">dimethylacetamide</ne> respectively at 70&lt;0&gt;C for 30 min.
The results are reported hereinbelow.
</P>
<P>1) At 100&lt;0&gt;C and with 2% of 2a in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.95" epochem-id="EPOCHEM:NEW:COMPOUND:753" name="DMPU" comment="" chebi-id="WO2007045405:224903" relevant="false">DMPU</ne>, 2a completely disappeared after 50 min. and Ib as crystalline <ne id="WO2007045405.HC.class-names.30" epochem-id="EPOCHEM:NEW:CLASS:1161" name="oxalate" comment="" chebi-id="CHEBI:30623" relevant="false" type="CLASS">oxalate</ne> was obtained in 84% yield, whereas in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.53" epochem-id="EPOCHEM:NEW:COMPOUND:746" name="dimethylacetamide" comment="" chebi-id="WO2007045405:145172" relevant="false">dimethylacetamide</ne> after the same time 13% of 2a remained unreacted and the reaction terminated with complete disappearance of 2a (which is the limiting substrate) after 180 min.
</P>
<P>2) At 100&lt;0&gt;C and with 10% of 2a in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.96" epochem-id="EPOCHEM:NEW:COMPOUND:753" name="DMPU" comment="" chebi-id="WO2007045405:224903" relevant="false">DMPU</ne>, 3% of 2a remained unreacted after 50 min., whereas in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.54" epochem-id="EPOCHEM:NEW:COMPOUND:746" name="dimethylacetamide" comment="" chebi-id="WO2007045405:145172" relevant="false">dimethylacetamide</ne> the percentage of unreacted 2a was 14%. The reaction was complete in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.97" epochem-id="EPOCHEM:NEW:COMPOUND:753" name="DMPU" comment="" chebi-id="WO2007045405:224903" relevant="false">DMPU</ne> after 90 min. and in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.55" epochem-id="EPOCHEM:NEW:COMPOUND:746" name="dimethylacetamide" comment="" chebi-id="WO2007045405:145172" relevant="false">dimethylacetamide</ne> after 300 min. (2a concentration lower than 1%).
</P>
<P>3) At 8O&lt;0&gt;C and with 2% of 2a in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.98" epochem-id="EPOCHEM:NEW:COMPOUND:753" name="DMPU" comment="" chebi-id="WO2007045405:224903" relevant="false">DMPU</ne> 2a completely disappeared after 50 min. and <ne id="WO2007045405.HC.class-names.31" epochem-id="EPOCHEM:NEW:CLASS:1161" name="oxalate" comment="" chebi-id="CHEBI:30623" relevant="false" type="CLASS">oxalate</ne> Ib was obtained in 85% yield, whereas in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.56" epochem-id="EPOCHEM:NEW:COMPOUND:746" name="dimethylacetamide" comment="" chebi-id="WO2007045405:145172" relevant="false">dimethylacetamide</ne> 4% of 2a was still unreacted after 300 min.. If the reaction is interrupted at this time, the resulting <ne id="WO2007045405.HC.class-names.32" epochem-id="EPOCHEM:NEW:CLASS:1161" name="oxalate" comment="" chebi-id="CHEBI:30623" relevant="false" type="CLASS">oxalate</ne> Ib is contaminated by 2a. The separation of <ne id="WO2007045405.HC.class-names.14" epochem-id="EPOCHEM:NEW:CLASS:429" name="oxalates" comment="" chebi-id="WO2007045405:918973" relevant="false" type="CLASS">oxalates</ne> 2a and Ib through fractional crystallization is difficult and involves remarkable losses. In the present case, the reaction crude from this experiment led to <ne id="WO2007045405.HC.class-names.33" epochem-id="EPOCHEM:NEW:CLASS:1161" name="oxalate" comment="" chebi-id="CHEBI:30623" relevant="false" type="CLASS">oxalate</ne> Ib with a content in 2a lower than 0.5% after 3 crystallizations from <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.129" epochem-id="EPOCHEM:COMPOUND:4306" name="ethyl acetate" comment="" chebi-id="CHEBI:27750" relevant="false">ethyl acetate</ne>/<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.77" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> and with a final yield of 48%. It is therefore of the utmost importance that upon completion of the reaction Ib is free from 2a, because the purification of the <ne id="WO2007045405.HC.class-names.15" epochem-id="EPOCHEM:NEW:CLASS:429" name="oxalates" comment="" chebi-id="WO2007045405:918973" relevant="false" type="CLASS">oxalates</ne> by fractional crystallization involves a remarkable decrease in yields.
</P>
<P>2.
Syhthesis of (+) and <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.80" epochem-id="EPOCHEM:NEW:COMPOUND:750" name="(-)-duIoxetine" comment="" chebi-id="WO2007045405:314268" relevant="true">(-)-duIoxetine</ne> Ia (+) And <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.83" epochem-id="EPOCHEM:NEW:COMPOUND:752" name="(-)-duloxetine" comment="" chebi-id="WO2007045405:594578" relevant="true">(-)-duloxetine</ne> Ia were obtained from racemic <ne id="WO2007045405.HC.class-names.34" epochem-id="EPOCHEM:NEW:CLASS:1161" name="oxalate" comment="" chebi-id="CHEBI:30623" relevant="false" type="CLASS">oxalate</ne> Ib according to a known method, hydrolysing Ib base from the <ne id="WO2007045405.HC.class-names.35" epochem-id="EPOCHEM:NEW:CLASS:1161" name="oxalate" comment="" chebi-id="CHEBI:30623" relevant="false" type="CLASS">oxalate</ne> by treatment with an excess of aqueous <ne type="FORMULA" id="WO2007045405.HC.formula-names.9" epochem-id="EPOCHEM:NEW:FORMULA:5" name="NaOH" comment="" chebi-id="CHEBI:32145" relevant="false">NaOH</ne> and extraction of the free base with <ne id="WO2007045405.HC.class-names.36" epochem-id="EPOCHEM:NEW:CLASS:1162" name="ethyl ether" comment="" chebi-id="CHEBI:35702" relevant="false" type="CLASS">ethyl ether</ne>. The free base was combined respectively with a non-natural and natural form of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.58" epochem-id="EPOCHEM:COMPOUND:157" name="tartaric acid" comment="" chebi-id="CHEBI:15674" relevant="false">tartaric acid</ne> to give, after three crystallizations of the crystalline salt from absolute <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.61" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne>, the salts of (+) and (-) Ia. The free bases were recovered by treatment with an excess of aqueous base and extraction with an <ne id="WO2007045405.HC.class-names.24" epochem-id="EPOCHEM:NEW:CLASS:1160" name="ether" comment="" chebi-id="CHEBI:25698" relevant="false" type="CLASS">ether</ne> <ne type="ONT" id="WO2007045405.HC.class-names.10" epochem-id="EPOCHEM:NEW:CLASS:770" name="solvent" comment="" chebi-id="CHEBI:46787" relevant="false">solvent</ne>. N-demethylation of (+) and (-) Ib was carried out by treatment with <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.81" epochem-id="EPOCHEM:NEW:COMPOUND:751" name="phenyl chloroformate" comment="" chebi-id="WO2007045405:272812" relevant="false">phenyl chloroformate</ne> in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.82" epochem-id="EPOCHEM:COMPOUND:5618" name="toluene" comment="" chebi-id="CHEBI:17578" relevant="false">toluene</ne> under reflux and subsequent basic hydrolysis in a high-boiling <ne type="ONT" id="WO2007045405.HC.class-names.11" epochem-id="EPOCHEM:NEW:CLASS:770" name="solvent" comment="" chebi-id="CHEBI:46787" relevant="false">solvent</ne>. (+) And <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.84" epochem-id="EPOCHEM:NEW:COMPOUND:752" name="(-)-duloxetine" comment="" chebi-id="WO2007045405:594578" relevant="true">(-)-duloxetine</ne> Ia were purified by crystallization of the corresponding <ne id="WO2007045405.HC.class-names.16" epochem-id="EPOCHEM:NEW:CLASS:429" name="oxalates" comment="" chebi-id="WO2007045405:918973" relevant="false" type="CLASS">oxalates</ne> and the free bases obtained as described above were converted to <ne id="WO2007045405.HC.class-names.37" epochem-id="EPOCHEM:NEW:CLASS:1163" name="hydrochlorides" comment="" chebi-id="CHEBI:36807" relevant="false" type="CLASS">hydrochlorides</ne> by treatment with gaseous <ne type="FORMULA" id="WO2007045405.HC.formula-names.10" epochem-id="EPOCHEM:NEW:FORMULA:106" name="HCl" comment="" chebi-id="CHEBI:17883" relevant="false">HCl</ne> in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.62" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne>. The solutions were evaporated to dryness and the residue was crystallized from boiling <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.63" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne>. The enantiomeric excess of the products, determined by HPLC on a Chiracel OD column (<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.85" epochem-id="EPOCHEM:COMPOUND:5452" name="hexane" comment="" chebi-id="CHEBI:29021" relevant="false">hexane</ne>/<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.86" epochem-id="EPOCHEM:NEW:COMPOUND:97" name="isopropanol" comment="" chebi-id="CHEBI:17824" relevant="false">isopropanol</ne>/<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.87" epochem-id="EPOCHEM:COMPOUND:4239" name="triethylamine" comment="" chebi-id="CHEBI:35026" relevant="false">triethylamine</ne>) was higher than 99.9%.
(+)-la <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.66" epochem-id="EPOCHEM:NEW:COMPOUND:455" name="hydrochloride" comment="" chebi-id="CHEBI:36807" relevant="false">hydrochloride</ne>: &lt;1&gt;H NMR (<ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.123" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne> - d6) [delta] (8.26 (IH, m), 7.85 (IH, m), 7.52 (2H, m), 7.45 (2H, m), 7.34 (IH, t, J = 8.0 Hz), 7.26 (IH, d, J = 3.2 Hz), 7.06 (IH, d, J = 7.6 Hz), 6.98 (IH, dd, J= 3.7, 4.8 Hz), 6.14 (IH, dd, J = 5.6, 7.3 Hz), 3.07 (2H, m), 2.55 (4H, m + s), 2.39 (IH, m); [[alpha]]D&lt;20&gt; = + 121 (c 1,00, <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.78" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne>).
CLAIM
A process for the preparation of <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.112" epochem-id="EPOCHEM:NEW:COMPOUND:1686" name="DULOXETINE" comment="" chebi-id="CHEBI:36796" relevant="true">duloxetine</ne> Ia:
EMI9.1
&lt;1 a&gt; comprising the reaction between <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.10" epochem-id="EPOCHEM:NEW:COMPOUND:735" name="1-fluoronaphthalene" comment="" chebi-id="WO2007045405:69693" relevant="true">1-fluoronaphthalene</ne> 3b
EMI9.2
</P>
<P>3b and <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.3" epochem-id="EPOCHEM:NEW:COMPOUND:734" name="3-N,N-dimethylamino-l-(2-thienyl)-propan-l-ol" comment="3-N,N-dimethylamino-1-(2-thienyl)-propan-1-ol" chebi-id="WO2007045405:87489" relevant="true">3-N,N-dimethylamino-l-(2-thienyl)-propan-l-ol</ne> 2a
EMI9.3
</P>
<P>2a to give <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.26" epochem-id="EPOCHEM:NEW:COMPOUND:736" name="((+)-(S)-N,N-dimethyl-[gamma]-(l-naphthalenyloxy)-2- thiophenepropanamine)" comment="" chebi-id="WO2007045405:788904" relevant="true">((+)-(S)-N,N-dimethyl-[gamma]-(l-naphthalenyloxy)-2- thiophenepropanamine)</ne> Ib:
EMI9.4
</P>
<P>1b and the conversion of Ib to <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.113" epochem-id="EPOCHEM:NEW:COMPOUND:1686" name="DULOXETINE" comment="" chebi-id="CHEBI:36796" relevant="true">duloxetine</ne> Ia, characterized in that the reaction between 2a and 3b is carried out in <ne type="CHEMICAL" id="WO2007045405.HC.chemical-names.28" epochem-id="EPOCHEM:NEW:COMPOUND:737" name="l,3-dimethyl-2-oxo-hexahydropyrimidine" comment="1,3-dimethyl-2-oxo-hexahydropyrimidine" chebi-id="WO2007045405:140567" relevant="true">l,3-dimethyl-2-oxo-hexahydropyrimidine</ne> as the <ne type="ONT" id="WO2007045405.HC.class-names.12" epochem-id="EPOCHEM:NEW:CLASS:770" name="solvent" comment="" chebi-id="CHEBI:46787" relevant="false">solvent</ne>.
</P></DIV>
<DIV><P>
</P></DIV>
</BODY>
</PAPER>
